MÇMerih Kızıl Çakar

Merih Kızıl Çakar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Merih Kızıl Çakar has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Bahar Uncu Ulu

    Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey

    17 shared publications
  • Fevzi Altuntaş

    Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey

    17 shared publications
  • Mehmet Sinan Dal

    Hematology Clinic and Bone Marrow Transplantation Unit, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey; Department of Hematology, Ankara Onkoloji Eğitim ve Araştırma Hastanesi, Ankara, Türkiye; Department of Hematology & Apheresis Unit, University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara, Turkey (Türkiye), Turkey (Türkiye)

    17 shared publications
  • Tuğçe Nur Yiğenoğlu

    Hematology and Bone Marrow Transplantation Unit, Ankara Oncology Training and Research Hospital, Health Sciences University, Ankara 06170, Turkey

    16 shared publications
  • Dicle İsKender

    Department of Hematology and Bone Marrow Transplantation Center, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey

    14 shared publications
  • Semih Başcı

    Department of Hematology, Faculty of Medicine, Dokuz Eylül University, 35340 İzmir, Türkiye

    13 shared publications

Latest Publications

  • Open Access

    C-Reactive Protein-to-Albumin Ratio (CAR) as a Prognostic Biomarker in Newly Diagnosed Acute Myeloid Leukemia Treated with Intensive Induction Therapy: A Single-Center Retrospective Cohort Study

    by Emine Merve Savaş, Aytek Peker, Selin Kucukyurt, Lale Aydın Kaynar, Jale Yıldız, Hacer Berna Afacan Öztürk, Merih Kızıl Çakar, Murat Albayrak, Şahika Zeynep Akı, Ahmet Kürşad Güneş

    Objective: Inflammation plays an important role in acute myeloid leukemia (AML) biology and may influence clinical outcomes. The C-reactive protein-to-albumin ratio (CAR) is a simple marker of systemic inflammation. We evaluated the prognostic value of baseline CAR in patients with AML treated with intensive therapy.Materials and Methods: We retrospectively analyzed 114 adults with newly diagnosed AML who were eligible for intensive induction therapy and received it (7+3 idarubicin and cytarabine regimen) at Ankara Etlik City Hospital between November 2022 and May 2025. CAR was calculated at diagnosis as CRP (mg/L) divided by serum albumin (g/L). Patients were stratified into low- and high-CAR groups according to the cohort median. Overall survival (OS) and progression-free survival (PFS) were estimated by the Kaplan–Meier method and compared with the log-rank test. Cox regression analysis was performed for OS.Results: The median age was 49 years, and 62 patients (54.4%) were male. OS was significantly longer in the low-CAR group than in the high-CAR group, with estimated 2-year OS rates of 78.0% and 55.6%, respectively (p=0.008). Similarly, PFS was significantly longer in the low-CAR group than in the high-CAR group, with estimated 2-year PFS rates of 65.9% and 44.1%, respectively (p=0.016). In ELN intermediate-risk patients, 2-year OS was significantly higher in the low-CAR group than in the high-CAR group (88.2% vs. 50.0%; p=0.021). Among non-transplanted patients, high CAR was associated with inferior OS (p=0.042). In multivariable analysis of ELN non-favorable-risk patients, high CAR [HR 4.63 (1.61–13.30); p=0.004] and absence of allo-HSCT [HR 6.39 (2.19–18.67); p=0.001] were independently associated with inferior OS.Conclusion: In newly diagnosed AML patients, CAR is a simple and accessible biomarker that may help predict survival. Although genetic risk stratification remains the cornerstone of prognostic assessment, CAR may provide additional prognostic information, particularly in patients with intermediate-risk AML.

  • Open Access

    Overview of Acute Myeloid Leukemia with TP53 Mutation: Single Center, Real-Life Data

    by Selin Kucukyurt, Hacer Berna Afacan Öztürk, Lale Aydın Kaynar, Jale Yıldız, Haktan Bağiş Erdem, Birgül Ay Karakuş, Murat Albayrak, Merih Kızıl Çakar, Şahika Zeynep Akı, Ahmet Kürşad Güneş

    Objective: Acute myeloid leukemia (AML) with TP53 mutations represents a distinct and high-risk molecular subgroup characterized by aggressive disease progression, chemoresistance, and poor survival outcomes. This study provides a single-center analysis of clinical characteristics, treatment responses, and survival outcomes in a real-world cohort of patients with TP53-mutated AML. Material and Method: A retrospective observational study was conducted at Ankara Etlik City Hospital, analyzing nine patients diagnosed with TP53-mutated AML between January 2023 and January 2024. Patients were treated with intensive or less intensive induction regimens based on patient-related factors. Cytogenetic and molecular abnormalities were recorded, alongside treatment responses were assessed per the European Leukemia Net 2022 guidelines. The primary endpoint was overall survival. Results: The median age at diagnosis was 65 years, with 55.5% female patients. Complex karyotypes were observed in 66.7% of cases, and multi-hit TP53 mutations were identified in two patients. A complete response was achieved in 75% of patients treated with intensive induction therapy (7+3), while a complete or partial response was achieved in 60% of patients receiving the azacitidine-venetoclax regimen. Six patients died within 12 months, predominantly due to infection, while the three surviving patients underwent for allogeneic hematopoietic stem cell transplantation (allo-HSCT). The median overall survival (OS) of the entire cohort was 9 months. Patients with TP53-mutated AML who underwent allo-HSCT exhibited significantly prolonged OS (p=0.01). Conclusion: The prognosisof TP53-mutated AML remains particularly poor, highlighting an urgent need for the development of novel therapeutic approaches to improve patient outcomes. While allo-HSCT offers a potential survival benefit, effective bridging therapies and post-transplant management are critical for improving outcomes in this high-risk population

  • Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma

    by Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Semih Başcı, Mehmet Bakırtaş, Derya Şahin, Tahir Darçın, Samet Yaman, Ersin Bozan, Sema Seçilmiş, Burcu Arslan Candır, et al.


  • Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients

    by Bahar Uncu Ulu, Mehmet Sinan Dal, Ipek Yönal Hindilerden, Olga Meltem Akay, Özgür Mehtap, Nurhilal Büyükkurt, Fehmi Hindilerden, Ahmet Kürşad Güneş, Tuğçe Nur Yiğenoğlu, Semih Başcı, et al.

    The prognosis is poor for relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) patients. The brentuximab vedotin (Bv) and bendamustine (B) combination has been used as a preferable salvage regimen in R/R cHL patient trials. We retrospectively evaluated response rates, toxicities, and the survival in R/R cHL patients treated with the BvB combination. In a multi-centre real-life study, 61 R/R HL patients received intravenous doses of 1.8 mg/kg Bv on the first day plus 90 mg/m2 B on the first and second days of a 21-day cycle as a second-line or beyond-salvage regimen. Patients’ median age at BvB initiation was 33 (range: 18–76 years). BvB was given as median third-line treatment for a median of four cycles (range: 2–11). The overall and complete response rates were 82% and 68.9%, respectively. After BvB initiation, the median follow-up was 14 months, and one- and two-year overall survival rates were 85% and 72%, respectively. Grade 3/4 toxicities included neutropenia (24.6%), lymphopenia (40%), thrombocytopenia (13%), anaemia (13%), infusion reactions (8.2%), neuropathy (6.5%), and others. The BvB combination could be given as salvage regimen aiming a bridge to autologous stem cell transplant (ASCT), in patients relapse after ASCT or to transplant-ineligible patients with manageable toxicity profiles.


  • Is the Optimal Timing First Complete Remission for Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma?

    by Bahar Uncu Ulu, Derya Şahi̇n, Tuğçe Nur YİĞENOĞLU, Merih Kizil Çakar, Mehmet Sinan Dal, Fevzi Altuntaş

  • Open Access

    Autologous Stem Cell Transplantation in Multiple Myeloma Patients Over 60 Years Old

    by Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Semih Başcı, Mehmet Bakırtaş, Derya Şahin, Tahir Darçın, Jale Yıldız, Alparslan Merdin, Nuran Ahu Baysal, Dicle İsKender, et al.

    The incidence of Multiple myeloma (MM) increases with age; two-thirds of the patients are older than 65 years. Induction treatment, including new agents such as thalidomide, bortezomib, and lenalidomide followed by a conditioning regimen and upfront autologous stem cell transplantation (ASCT), has been accepted the standard treatment approach for newly diagnosed fit MM patients. We aimed to search the real-life data, the efficacy and safety of upfront ASCT following induction in patients with MM over 60 years old retrospectively. The data of MM patients who were ≥60 years old during autologous stem cell transplantation and treated at our center between 2010 and 2018 retrospectively analyzed. The study results were 63 patients included at the age of ≥ 60 years who underwent upfront ASCT. Median PFS was 15.5±2.6 months, and the median overall survival (OS) was 28.15±5 months. According to age groups, median PFS was 12±2.3 months in the 60-64 age group, 18.4±6 months in the 65-69 age group, and 26±15 months in the ≥70 age group. Median OS was 26.5±6.1 months in the 60-64 age group, 39.66±8.9 months in the 65-69 age group, and 18 months in the ≥70 age group. A significant relationship between the quantity of infused CD34+ stem cells and PFS and OS (p:0.05 and p<0.00, respectively). Our study indicated that a high dose (200 mg/m2 ) melphalan could safely be used in the physically fit patients at the ages of 60-69, and a reduced amount (140 mg/m2 ) would be the appropriate dose for the patients over 70. The quantity of infused CD34+ stem cells affect elderly MM patients; mobilization dynamics are also important factors for elderly myeloma. Age itself should not consider a barrier to ASCT, and a comprehensive geriatric evaluation should perform on elderly patients

  • Open Access

    Autologous Stem Cell Transplantation in Multiple Myeloma Patients Over 60 Years Old

    by Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Semih Başcı, Mehmet Bakırtaş, Derya Şahin, Tahir Darçın, Jale Yıldız, Alparslan Merdin, Nuran Ahu Baysal, Dicle İsKender, et al.

    The incidence of Multiple myeloma (MM) increases with age; two-thirds of the patients are older than 65 years. Induction treatment, including new agents such as thalidomide, bortezomib, and lenalidomide followed by a conditioning regimen and upfront autologous stem cell transplantation (ASCT), has been accepted the standard treatment approach for newly diagnosed fit MM patients. We aimed to search the real-life data, the efficacy and safety of upfront ASCT following induction in patients with MM over 60 years old retrospectively. The data of MM patients who were ≥60 years old during autologous stem cell transplantation and treated at our center between 2010 and 2018 retrospectively analyzed. The study results were 63 patients included at the age of ≥ 60 years who underwent upfront ASCT. Median PFS was 15.5±2.6 months, and the median overall survival (OS) was 28.15±5 months. According to age groups, median PFS was 12±2.3 months in the 60-64 age group, 18.4±6 months in the 65-69 age group, and 26±15 months in the ≥70 age group. Median OS was 26.5±6.1 months in the 60-64 age group, 39.66±8.9 months in the 65-69 age group, and 18 months in the ≥70 age group. A significant relationship between the quantity of infused CD34+ stem cells and PFS and OS (p:0.05 and p<0.00, respectively). Our study indicated that a high dose (200 mg/m2 ) melphalan could safely be used in the physically fit patients at the ages of 60-69, and a reduced amount (140 mg/m2 ) would be the appropriate dose for the patients over 70. The quantity of infused CD34+ stem cells affect elderly MM patients; mobilization dynamics are also important factors for elderly myeloma. Age itself should not consider a barrier to ASCT, and a comprehensive geriatric evaluation should perform on elderly patients

  • Open Access

    Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience

    by Hikmettullah Batgi̇, Semih Başci, Mehmet Sinan Dal, Merih Kizil Çakar, Bahar Uncu Ulu, Tuğçe Nur YİĞENOĞLU, Nurgül Özcan, Ali Kilinç, Alparslan Merdi̇n, Jale Yildiz, et al.

    GDP (gemcitabine, dexamethasone and cisplatin) is a well-established salvage regimen for relapsed and refractory lymphomas. In this study, we aimed to share our experience with the patients who received GDP/R-GDP (rituximab-gemcitabine, dexamethasone and cisplatin) for stem cell mobilization. Data of 69 relapsed and refractory Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patients who received GDP/R-GDP as salvage chemotherapy in our center between July 2014 and January 2020 were retrospectively evaluated. After the evaluation of response, 52 patients had a chemosensitive disease and underwent mobilization with GDP/R-GDP plus G-CSF (granulocyte colony-stimulating factor). Collected CD34+ stem cells and related parameters were compared in terms of diagnosis of HL and NHL, early and late stage, patients who did not receive RT and those who received RT, and patients aged under 60 and over 60. On the 15th day on average (range 11?20), median 8.7 × 106 /kg (4.1 - 41.5) CD34+ stem cells were collected in 51 (98%) of our 52 chemosensitive patients and 1 (2%) patients failed to mobilize. We observed acceptable hematological and non-hematological toxicity. The targeted amount of 2 × 106 /kg CD34+ stem cells was attained by 98% (n: 51) patients, and all of them underwent autologous stem cell transplantation. Moreover, low toxicity profiles provide outpatient utilization option clinics with close follow-up and adequate supportive care. We suggest that GDP/R-GDP plus G-CSF can be used as an effective chemotherapy regimen for mobilizing CD34+ stem cells from peripheral blood in relapsed and refractory lymphoma patients due to low toxicity, effective tumor reduction, and successful stem cell mobilization. It can also be assumed that the GDP mobilization regimen may be more effective, especially in patients with early-stage disease and in HL patients.


  • Open Access

    Efficacy of reduced dose melphalan conditioning for multiple myeloma patients undergoing autologous stem cell transplantation: in the era of combined induction with novel agents

    by Bahar Uncu Ulu, Mehmet Bakirtaş, Tuğçe Nur YİĞENOĞLU, Semih Başci, Jale Yildiz, Derya Şahi̇n, Tahir Darçin, Alparslan Merdi̇n, Hikmetullah Batgi̇, Dicle İskender, et al.

    Introduction / Aim: Melphalan 200 mg/m2 (MEL 200) is known as the standard conditioning regimen for Multiple Myeloma (MM) patients in autologous stem cell transplantation(ASCT). Most of the studies showing the superiority of MEL 200 versus melphalan 140 mg/m2 (MEL 140) were performed in the era of conventional chemotherapies. However, today, several novel agents such as proteasome inhibitors, immunomodulatory agents have been introduced in MM treatment algorithms. There is limited data on the impact of this dose reduction on progression-free survival (PFS) or overall survival (OS). The present study compares MEL 140 and MEL 200 conditioning for ASCT in patients treated with combination therapy of bortezomib‑containing induction. Material and Method: Results of 84 MM patients who underwent ASCT at our center between 2010 and 2018 were analyzed retrospectively. Findings / Results: In the MEL 140 group, PFS was 9 months (%95 CI 2.2-15.8) and OS was 30 months ( %95CI 9.5-50.4), while PFS was 13 months ( %95CI 10.5-15.5) and OS was 34 months( %95CI 6.9-61) in the MEL 200 group. There was no statistically significant difference in PFS and OS between the two groups (p:0.6, p:0.7). Conclusion: Consequently, MEL 140 and MEL 200 were found similar in terms of engraftment duration, transplant-related mortality rate, and survival rates. The idea that similar outcomes in both MEL 140 and MEL 200 group in patients who received combined induction treatment with novel agent suggested that MEL 140 may be used more commonly than the standard approach of MEL 200. ÖZET Giriş: Multipl Myeloma (MM) tedavisinde 200 mg/m2 melfalan (MEL 200) otolog kök hücre nakli (OKHN) için standart hazırlama rejimi olarak kabul edilmiştir. MEL 200’ün 140 mg/m2 melfalan’a (MEL 140) üstünlüğünü gösteren çalışmaların çoğu konvansiyonel kemoterapiler döneminde yapılmıştır. Ancak günümüzde MM tedavisine immünmodulatuvar, proteozome inhibitörü gibi birçok yeni ajan katılmıştır. Bu çalışmada indüksiyon tedavisinde bortezomib içeren kombinasyon tedavisi almış hastaların otolog kök hücre nakli ile konsalidasyonunda MEL 140 ve MEL 200’un karşılaştırılması hedeflendi. Materyal Metot: 2010-2018 yılları arasında merkezimizde OKHN olmuş 84 MM hastasının sonuçları geriye dönük olarak analiz edildi. Bulgular: MEL 140 grubunda progresyonsuz sağkalım (PFS) 9 ay (%95 CI 2.2-15.8), genel sağkalım (OS) 30 ay (%95CI 9.5-50.4) saptanırken MEL 200 grubunda PFS 13 ay ( %95CI 10.5-15.5) , OS 34 ay ( %95CI 6.9-61) saptandı. Her 2 grup arasında PFS ve OS açısından istatistiksel olarak anlamlı bir fark saptanmadı (sırasıyla p:0.6; p:0.7). Sonuç: Sonuç olarak, engraftman süreleri, transplant ilişkili mortalite oranı ve sağkalım oranları açısından MEL 140 ve MEL 200 benzer bulundu. İndüksiyon tedavisinde yeni ajanlar ile kombine tedaviler almış olan hastalarda MEL 140 ve MEL 200 arasında OS ve PFS farkı olmaması, standart yaklaşım olan MEL 200 yerine MEL 140’ın daha yaygın kullanabileceği fikrini doğurmuştur.

  • Evaluation of risk factors and causative pathogens in bloodstream infections in Cancer Patients

    by Duygu Mert, Alparslan Merdin, Nurten Kandemir, Merih Kızıl Çakar, Ece Dirim, Sabahat Çeken, Fevzi Altuntaş, Mustafa Ertek